Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 12/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021734 | 0.92 | LCK (0.47) | MAP3K14LCKROCK1HASPINKDM4E | |
| SCHEMBL7024505 | 0.84 | ROCK1 (0.51) | LCKROCK1MKNK2 | |
| SCHEMBL7021644 | 0.83 | MAP3K14 (0.39) | MAP3K14LCKROCK1HASPINKDM4E | |
| SCHEMBL7024457 | 0.81 | LCK (0.55) | MAP3K14LCKROCK1 | |
| SCHEMBL7022025 | 0.79 | MAP3K14 (0.36) | MAP3K14LCKROCK1HASPINKDM4E | |
| SCHEMBL7019434 | 0.78 | LCK (0.49) | MAP3K14LCKHASPINKDM4EGPR84 | |
| SCHEMBL7555673 | 0.72 | MAPT (0.39) | LCKMEN1KMT2AMKNK2 | |
| SCHEMBL7018051 | 0.71 | LCK (0.55) | MAP3K14LCKROCK1GAAHSD17B10 | |
| SCHEMBL7017821 | 0.70 | LCK (0.56) | MAP3K14LCKROCK1MKNK2 | |
| SCHEMBL7021631 | 0.68 | GPR84 (0.47) | HASPINKDM4EMEN1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1194152-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1206260-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206260-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1194152-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6329380-B1 | PYRIMIDINE BENZIMIDIZAZOLE, PYRIMIDINEIMIDAZOLE OR PYRIDINE IMIDAZOLE COMPOUNDS FOR ANTICANCER AGENTS OR ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-12-11 | — | — | US | disclosed |
| US-6316444-B1 | SRC kinase inhibitor compounds | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001000207-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000214-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |